ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Neutropenia"

  • 2021 American Transplant Congress

    Outcomes Among CMV Mismatched and Highly Sensitized Kidney Transplant Recipients Who Develop Leukopenia or Neutropenia

    S. Brar1, R. Berry2, A. Raval3, Y. Tang3, F. Vincenti2, N. Skartsis2

    1University of British Columbia, Vancouver, BC, Canada, 2University of California, San Francisco, San Francisco, CA, 3Merck and Co., Inc., Kenilworth, NJ

    *Purpose: Kidney transplant recipients (KTRs) who receive antiproliferative agents for immunosuppression and valganciclovir for CMV prophylaxis are at high risk of developing leukopenia and neutropenia.…
  • 2021 American Transplant Congress

    Outcomes of Granulocyte-Colony Stimulating Factor Use in Pediatric Renal Transplant Recipients: A Pediatric Nephrology Research Consortium Study

    R. M. Engen1, P. L. Weng2, W. Shih3, H. Patel4, K. Richardson5, S. Dowdrick6, I. Ashoor7, J. Misurac8, A. Z. Traum9, M. Semanik10, N. G. Jain11, R. Sreedharan12

    1Northwestern University, Chicago, IL, 2University of California Los Angeles, Los Angeles, CA, 3University of Michigan, Ann Arbor, MI, 4Nationwide Children's Hospital, Columbus, OH, 5Oregon Health & Science University, Portland, OR, 6Penn State Health, Hershey, PA, 7Louisiana State University, New Orleans, LA, 8University of Iowa, Iowa City, IA, 9Harvard University, Boston, MA, 10University of Wisconsin-Madison, Madison, WI, 11Columbia University, New York, NY, 12Medical College of Wisconsin, Milwaukee, WI

    *Purpose: Neutropenia is common after pediatric kidney transplant and is associated with an increased risk of bacterial infection, allograft loss, and death. Granulocyte colony-stimulating factor…
  • 2020 American Transplant Congress

    Evaluation of the Safety and Efficacy of Valganciclovir to Prevent Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients Utilizing Two Dosing Regimens

    K. Le, A. Patel, N. M. Jasiak-Panek

    Pharmacy, Ann and Robert H. Lurie Children's Hospital, Chicago, IL

    *Purpose: Valganciclovir (VGCV) is FDA-approved for CMV prophylaxis in children aged one month to sixteen years old using the Pescovitz algorithm (7 x body surface…
  • 2020 American Transplant Congress

    Outcomes in Liver Transplantation with Use of Granulocyte-Colony Stimulating Factor

    K. Schnelle, A. Leino, M. Chunduru, L. Von Stein, O. Witkowsky

    The Ohio State Wexner Medical Center, Columbus, OH

    *Purpose: Questions remain if treatment with a granulocyte-colony stimulating factor (G-CSF) impacts clinical outcomes after liver transplant. The purpose of this study was to compare…
  • 2020 American Transplant Congress

    Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant

    K. Gandhi, D. Masic, M. Santarossa, F. Albarillo, N. Clark, G. Reid

    Loyola University Medical Center, Maywood, IL

    *Purpose: At centers where antiviral prophylaxis is used after solid organ transplant, valganciclovir is administered for the prevention of cytomegalovirus (CMV). At Loyola University Medical…
  • 2020 American Transplant Congress

    Granulocyte Colony Stimulating Factor: Trigger of Rejection in Lung Transplantation?

    K. Walter1, M. Patti1, S. Khalid2, L. Kemp1, L. J. Lobo3, R. Coakley3, S. Krishnan3, C. T. Doligalski1

    1University of North Carolina Medical Center, Chapel Hill, NC, 2Eshelman School of Pharmacy, Chapel Hill, NC, 3Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

    *Purpose: Granulocyte colony stimulating factor (GCSF) is a management strategy for post-transplant neutropenia, but may increase the risk of rejection in lung transplant recipients (LTRs).…
  • 2020 American Transplant Congress

    Renal Transplant Induction Therapy Safety Outcomes Comparison

    R. M. Hofmann1, J. Combs2, K. J. Schmidt3, T. Dyckman4

    1Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, 2Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, 3Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, 4Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI

    *Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…
  • 2020 American Transplant Congress

    Filgrastim Utilization Evaluation in Solid Organ Transplant Recipients

    O. Witkowsky, L. Stanz, K. Schnelle

    The Ohio State University Wexner Medical Center, Columbus, OH

    *Purpose: Neutropenia occurs in up to 40% of kidney and liver transplant (txp) recipients and has been associated with higher mortality rates in liver txp.…
  • 2019 American Transplant Congress

    Alemtuzumab Induction in Living Donor Renal Transplantation

    O. Witkowsky, H. Winters, K. Washburn, G. Bumgardner, A. Rajab, A. El-Hinnawi, T. Pesavento

    The Ohio State University Wexner Medical center, Columbus, OH

    *Purpose: About 15% of kidney transplant (KT) recipients receive alemtuzumab (ALM) for induction. The aim of this study was to review outcomes in living donor…
  • 2019 American Transplant Congress

    Safety Outcomes in Elderly Patients Who Receive Alemtuzumab Induction for Kidney Transplant

    S. Anders, A. Freeman, A. Mohammed, L. Hutchinson, U. Kaszubski, M. Janusek, J. Garces, H. Bohorquez

    Ochsner Clinic Foundation, New Orleans, LA

    *Purpose: As a consequence of natural immunosenescence, elderly patients may not require as potent immunosuppression as their younger counterparts. Optimal induction regimens in this population,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences